Storck J, Zimmermann E R
Institute of Vegetative Physiology, University of Münster, Germany.
Thromb Res. 1996 Jan 1;81(1):121-31. doi: 10.1016/0049-3848(95)00220-0.
At present only little information is available about the regulation of the thrombin receptor activity in human endothelial cells. The study presented was performed to clarify the problem of thrombin receptor regulation in human endothelial cells. Endothelial cells were isolated from the vein or artery of human umbilical cords. These cells were stimulated with thrombin or with the thrombin receptor activation peptides (TRAP) SFLLRN or SFLLRNPNDKYEPF and subsequently the von Willebrand factor (vWf) release was measured as a physiologically significant response regarding the thrombin receptor activation. Shortly after the first activation by thrombin or SFLLRN, the cells were desensitised to a second stimulation. After a recovery phase of 10 min, merely 35% of the receptor response was obtained by subsequent stimulation. Expanding the recovery time to 90 min resulted in a vWf release of nearly 100% of the amount measured after the first stimulation. The resensitisation rate was similar for thrombin and SFLLRN stimulated cells. Adding RNA synthesis inhibitors or protein synthesis inhibitors had no effect on the recovery of the receptor response. Therefore, a de novo synthesis of receptor protein must be excluded as a means of resensitising endothelial cells to thrombin. It was shown that the dephosphorylation of tyrosine kinase inactivated receptors is also not responsible for receptor regeneration. These results prove that endothelial cells are capable of developing full thrombin receptor activity after a relatively short recovery phase of only 60-90 min as compared to the recovery phase of 16-24 h in megacaryoblastic cell lines. Desensitisation is similar in thrombin and TRAP stimulated cells. We assumed a transport mechanism for intracellular stored vesicles for receptor resensitisation; a co-localisation with vWf in the Weibel-Palade bodies is improbable.
目前,关于人内皮细胞中凝血酶受体活性的调节,仅有少量信息可用。本研究旨在阐明人内皮细胞中凝血酶受体调节的问题。内皮细胞从人脐带静脉或动脉中分离出来。用凝血酶或凝血酶受体激活肽(TRAP)SFLLRN或SFLLRNPNDKYEPF刺激这些细胞,随后测量血管性血友病因子(vWf)的释放,作为与凝血酶受体激活相关的生理显著反应。在首次被凝血酶或SFLLRN激活后不久,细胞对第二次刺激产生脱敏。经过10分钟的恢复阶段后,后续刺激仅获得35%的受体反应。将恢复时间延长至90分钟,导致vWf释放量接近首次刺激后测量值的100%。凝血酶和SFLLRN刺激的细胞的再敏化率相似。添加RNA合成抑制剂或蛋白质合成抑制剂对受体反应的恢复没有影响。因此,必须排除受体蛋白的从头合成作为内皮细胞对凝血酶再敏化的一种方式。结果表明,酪氨酸激酶失活受体的去磷酸化也与受体再生无关。这些结果证明,与巨核母细胞系中16 - 24小时的恢复阶段相比,内皮细胞能够在仅60 - 90分钟的相对较短恢复阶段后恢复完全的凝血酶受体活性。凝血酶和TRAP刺激的细胞中的脱敏情况相似。我们假设细胞内储存囊泡的转运机制用于受体再敏化;不太可能与Weibel-Palade小体中的vWf共定位。